INKT
Price:
$0.6503
Market Cap:
$25.72M
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.[Read more]
Industry
Biotechnology
IPO Date
2021-10-15
Stock Exchange
NASDAQ
Ticker
INKT
According to MiNK Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.76. This represents a change of 0.59% compared to the average of -1.75 of the last 4 quarters.
The mean historical PE Ratio of MiNK Therapeutics, Inc. over the last ten years is -10.46. The current -1.76 PE Ratio has changed 1.58% with respect to the historical average. Over the past ten years (40 quarters), INKT's PE Ratio was at its highest in in the March 2023 quarter at 0.10. The PE Ratio was at its lowest in in the December 2020 quarter at -55.49.
Average
-10.46
Median
-6.46
Minimum
-25.32
Maximum
-1.64
Discovering the peaks and valleys of MiNK Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 65.29%
Maximum Annual PE Ratio = -1.64
Minimum Annual Increase = -74.49%
Minimum Annual PE Ratio = -25.32
Year | PE Ratio | Change |
---|---|---|
2023 | -1.64 | -53.84% |
2022 | -3.55 | -45.09% |
2021 | -6.46 | -74.49% |
2020 | -25.32 | 65.29% |
The current PE Ratio of MiNK Therapeutics, Inc. (INKT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.88
5-year avg
-10.46
10-year avg
-10.46
MiNK Therapeutics, Inc.’s PE Ratio is less than Affimed N.V. (-0.52), less than ImmunoGen, Inc. (322.18), greater than Adaptimmune Therapeutics plc (-3.77), greater than Sangamo Therapeutics, Inc. (-3.14), greater than Day One Biopharmaceuticals, Inc. (-15.70), less than Acumen Pharmaceuticals, Inc. (-1.60), greater than X4 Pharmaceuticals, Inc. (-5.15), less than Inozyme Pharma, Inc. (-1.72), greater than VectivBio Holding AG (-7.94), greater than Terns Pharmaceuticals, Inc. (-5.73), less than HOOKIPA Pharma Inc. (-0.72), less than Kineta, Inc. (-0.36), greater than Candel Therapeutics, Inc. (-3.31), less than Forte Biosciences, Inc. (-1.42), less than AlloVir, Inc. (-0.59), greater than Monte Rosa Therapeutics, Inc. (-6.66), greater than Design Therapeutics, Inc. (-7.58), less than Werewolf Therapeutics, Inc. (-1.32), less than Ikena Oncology, Inc. (-1.35), greater than Stoke Therapeutics, Inc. (-7.05),
Company | PE Ratio | Market cap |
---|---|---|
-0.52 | $38.37M | |
322.18 | $8.73B | |
-3.77 | $169.37M | |
-3.14 | $423.55M | |
-15.70 | $1.38B | |
-1.60 | $130.67M | |
-5.15 | $73.33M | |
-1.72 | $168.31M | |
-7.94 | $1.06B | |
-5.73 | $551.25M | |
-0.72 | $24.14M | |
-0.36 | $7.05M | |
-3.31 | $175.37M | |
-1.42 | $38.45M | |
-0.59 | $58.94M | |
-6.66 | $595.94M | |
-7.58 | $362.37M | |
-1.32 | $83.33M | |
-1.35 | $80.59M | |
-7.05 | $698.63M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MiNK Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like MiNK Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is MiNK Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for MiNK Therapeutics, Inc. (INKT)?
What is the highest PE Ratio for MiNK Therapeutics, Inc. (INKT)?
What is the 3-year average PE Ratio for MiNK Therapeutics, Inc. (INKT)?
What is the 5-year average PE Ratio for MiNK Therapeutics, Inc. (INKT)?
How does the current PE Ratio for MiNK Therapeutics, Inc. (INKT) compare to its historical average?